Tempus AI’s (TEM) “Buy” Rating Reaffirmed at TD Cowen

Tempus AI (NASDAQ:TEM)‘s stock had its “buy” rating restated by analysts at TD Cowen in a research report issued to clients and investors on Wednesday,Benzinga reports. They presently have a $74.00 target price on the stock. TD Cowen’s price target would suggest a potential upside of 19.64% from the company’s current price.

Several other equities research analysts have also recently commented on TEM. Needham & Company LLC reissued a “buy” rating and issued a $56.00 target price on shares of Tempus AI in a research note on Tuesday, January 14th. Loop Capital dropped their price target on Tempus AI from $57.00 to $52.00 and set a “buy” rating on the stock in a research report on Tuesday, January 14th. Bank of America boosted their price objective on Tempus AI from $52.00 to $54.00 and gave the company a “neutral” rating in a research report on Friday, December 13th. Piper Sandler restated a “neutral” rating and set a $70.00 target price (up from $40.00) on shares of Tempus AI in a report on Tuesday, November 12th. Finally, Stifel Nicolaus lowered shares of Tempus AI from a “buy” rating to a “hold” rating and raised their price objective for the stock from $45.00 to $65.00 in a report on Monday, November 11th. Three investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $58.55.

Tempus AI Stock Up 0.5 %

Shares of TEM stock opened at $61.85 on Wednesday. The company has a debt-to-equity ratio of 8.17, a current ratio of 2.69 and a quick ratio of 2.55. Tempus AI has a 12-month low of $22.89 and a 12-month high of $79.49. The firm has a 50-day moving average price of $44.20 and a 200 day moving average price of $48.58.

Insider Activity

In other Tempus AI news, major shareholder Bradley A. Keywell sold 395,800 shares of the firm’s stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $42.95, for a total value of $16,999,610.00. Following the transaction, the insider now directly owns 16,164,449 shares of the company’s stock, valued at $694,263,084.55. This trade represents a 2.39 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Ryan M. Bartolucci sold 13,770 shares of Tempus AI stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $60.00, for a total transaction of $826,200.00. Following the completion of the transaction, the chief accounting officer now directly owns 57,237 shares in the company, valued at $3,434,220. This trade represents a 19.39 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 2,037,702 shares of company stock valued at $89,449,651.

Institutional Investors Weigh In On Tempus AI

Several hedge funds and other institutional investors have recently made changes to their positions in TEM. Kovitz Investment Group Partners LLC bought a new position in Tempus AI in the third quarter valued at about $1,367,000. China Universal Asset Management Co. Ltd. acquired a new position in shares of Tempus AI in the fourth quarter valued at approximately $1,091,000. Sumitomo Mitsui Trust Group Inc. raised its holdings in Tempus AI by 1,591.2% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,217,699 shares of the company’s stock valued at $68,922,000 after buying an additional 1,145,698 shares during the last quarter. Captrust Financial Advisors acquired a new stake in Tempus AI during the 3rd quarter worth approximately $2,726,000. Finally, Sigma Planning Corp bought a new stake in Tempus AI during the 3rd quarter worth approximately $1,323,000. 24.22% of the stock is owned by institutional investors.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.